The story of Sildenafil presents a interesting case for investors in the pharmaceutical sector. While initially a tremendous success, creating billions, the intellectual property lapse and the subsequent arrival of generic versions have significantly impacted revenue. This raises questions about the future viability of related therapeutic innovatio